l-VWH : EMF )543F, EMF+@,,F\PEMF+"@ @ $@ 0@?!@ @ F(GDIC,FmmEMF+*@$??@xlll\ll]s-) EMF\l )543F, EMF+@,,F\PEMF+"@ @ $@ 0@?!@ @     !" !" !  " !  a" !  aRp MS Sans Serif0?v x:vfvxz0&'&ښ0`$vP(0P`$vN0P`$v8ƭtj0n' 5s Serifߦ0 &9 Y!`$v'&dv% % " !%   o]  Td&o{A9vA&mLTRkngTHoS{A9vAHmL|Empresas/Organizaciones% !  T(o {A9vA(m LdU$ gastados % " !%   aRp"MS Sans Serif0?v Pxvfvx0&&&ښ0~vP(0P~vN0P~vhítj0p& 5s Serifߦ0 a&e !~v'&dv%   TTOe{A9vAOLP1TlG{A9vALXPhRMA#FTvE{A9vAv L`20.220.000  wTv{A9vA L` TTw{A9vAwLP TTOe{A9vAOLP2TI{A9vA L`Eli Lilly    FTvE{A9vAv L`12.485.000  wTv{A9vA L` TTw{A9vAwLP TTOe<{A9vAOLP3Tx0<{A9vAL\Pfizer   F4TvE<{A9vAv L`12.180.000  w4Tv<{A9vA L` TTw<{A9vAwLP TTOBep{A9vAOBLP4TpBHp{A9vABLXAmgen $ FhTvBEp{A9vAvB L`10.150.000  whTBvp{A9vAB L` TTwBp{A9vAwBLP  TTOve{A9vAOvLP5Tv{A9vAvLhSanofi-aventis  FTvE{A9vAv L`7.159.000  Tv{A9vAv Ld TTv{A9vAvLP I TTOe{A9vAOLP6eT{A9vALlGlaxoSmithKline ! $  FTE{A9vA L`6.990.000t  T{A9vA Ld TT{A9vALP TTOe {A9vAOLP7 T|m {A9vAL\Bayer AG !FTE {A9vA L`6.322.430   T {A9vA Ld TT {A9vALP 1 TTOe@{A9vAOLP8aT@{A9vALpBarr Laboratories   F8TE@{A9vA L`6.290.000b  8T@{A9vA Ld TT@{A9vALP TTOFet{A9vAOFLP9oTFt{A9vAF LdRoche Group  !FlTFEt{A9vAF L`5.772.772d  lTFt{A9vAF Ld TTFt{A9vAFLP 1 TXDzq{A9vADzLP10Tz{A9vAz LdNovartis AG0  !FTzE{A9vAz L`5.314.420a  Tz{A9vAz Ld TTz{A9vAzLP u TXDq{A9vADLP11T{A9vA L`Merck KGaA# !FTE{A9vA L`4.640.000   T{A9vA Ld TT{A9vALP o TXDq{A9vADLP12T#{A9vALtAbbott Laboratories    FTE{A9vA L`4.640.000r  T{A9vA Ld TT{A9vALP TXDqD{A9vADLP13TD{A9vA LdAstraZeneca   F<TED{A9vA L`4.340.000  <TD{A9vA Ld TTD{A9vALP TXDJqx{A9vADJLP14TJ9x{A9vAJLtBristol-Myers Squibb   #  FpTJEx{A9vAJ L`3.545.520  pTJx{A9vAJ Ld TTJx{A9vAJLP TXD~q{A9vAD~LP15Tl~0{A9vA~LXWyeth* FT~E{A9vA~ L`3.302.568  T~{A9vA~ Ld TT~{A9vA~LP TXDq{A9vADLP16T{A9vA LdMedicines Co#   FTE{A9vA L`3.240.000  T{A9vA Ld TT{A9vALP TXDq{A9vADLP17Tl"{A9vALXTeva  F TE{A9vA L`2.210.000   T{A9vA Ld TT{A9vALP TXDqH{A9vADLP18TH{A9vALlSchering-Plough    F@TEH{A9vA L`2.160.000  @TH{A9vA Ld TTH{A9vALP TXDNq|{A9vADNLP19TNu|{A9vAN L`Cephalon   FtTNE|{A9vAN L`1.946.008  tTN|{A9vAN Ld TTN|{A9vANLP % " !%   ]  TXDq{A9vADLP20TY{A9vA"LGeneric Pharmaceutical Association!  $    FTE{A9vA L`1.940.244  T{A9vA Ld TT{A9vALP % " !%   aRp MS Sans Serif0?v x:vfvxz0& &ښ0(&vP(0P(&vN0P(&v(ǭtj0\ 5s Serifߦ0  &" !!(&v'&dv% % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % " !%   \i% % % % % %   TxE&5{A9vAE2LTOP 20 CLIENTES FARMACUTICOS PARA LOS "LOBISTAS" !    # !  ! !  T;h{A9vA;LtPROFESIONALES (2008)! ! % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % " !%   \% %   T{A9vADLFuente: The Center for Responsive Politics y elaboracin de ctsbrief                  % % % " !%   a% " !%   ^'%   &% 6% Ld!??% 6% Ld1!??%  6 % Ld   !??%  6 % Ld   1!??% >6>% Ld>A>!??% >6>% Ld>A>1!??% r6r% Ldrur!??% r6r% Ldrur1!??% 6% Ld!??% 6% Ld1!??% 6% Ld!??% 6% Ld1!??% 6% Ld!??% 6% Ld1!??% B6B% LdBEB!??% B6B% LdBEB1!??% v6v% Ldvyv!??% v6v% Ldvyv1!??% 6% Ld!??% 6% Ld1!??% 6% Ld!??% 6% Ld1!??% 6% Ld!??% 6% Ld1!??% F6F% LdFIF!??% F6F% LdFIF1!??% z6z% Ldz}z!??% z6z% Ldz}z1!??% 6% Ld!??% 6% Ld1!??% 6% Ld!??% 6% Ld1!??% 6% Ld!??% 6% Ld1!??% J6J% LdJMJ!??% J6J% LdJMJ1!??% ~6~% Ld~~!??% ~6~% Ld~~1!??LdiiR!??LdqqJ!??LdqqJ!??LdXq]XqJ!??Ldi]piZ!??Ld]Z!??% 6X% LdWk!??%  6X % Ld W  k!??% >6X>% Ld>WA>k!??% r6Xr% LdrWurk!??% 6X% LdWk!??% 6X% LdWk!??% 6X% LdWk!??% B6XB% LdBWEBk!??% v6Xv% LdvWyvk!??% 6X% LdWk!??% 6X% LdWk!??% 6X% LdWk!??% F6XF% LdFWIFk!??% z6Xz% LdzW}zk!??% 6X% LdWk!??% 6X% LdWk!??% 6X% LdWk!??% J6XJ% LdJWMJk!??% ~6X~% Ld~W~k!??Ld]Z!??% ( % " !%   a% ( ( ( " F4(EMF+*@$??FEMF+@ @$@@47DDTaKDbCEbCTaKDvD!b !!s % % % 0        : # ??@KDC$$??@KDCs -Rp"System@ |]|B   &O! nّ|@@$@$@8$@+T|@$xB(||| @? |`|]|r|A"|L`A^ZwAp$wdv% F(GDIC^    !" !" # ??@KDC$$??@KDC!  " !  a" !  aRp MS Sans Serif0?v x:vfvxz0&'&ښ0`$vP(0P`$vN0P`$v8ƭtj0n' 5s Serifߦ0 &9 Y!`$v'&dv% Rp"System' 5s Serifߦ0 &9 Y!`$v&dv@`@^Zw@p$wv %` s@w O!@"wO!%i  @wO!i dv% " !%   o]  TdS^{A9vA&mLTRkngTu^{A9vAHmL|Empresas/Organizaciones% !  TU^M{A9vA(m LdU$ gastados % " !%   aRp"MS Sans Serif0?v Pxvfvx0&&&ښ0~vP(0P~vN0P~vhítj0p& 5s Serifߦ0 a&e !~v'&dv%   TT|{A9vAOLP1Tlt{A9vALXPhRMA#FTr{A9vAv L`20.220.000  wT,{A9vA L` TT{A9vAwLP TT|{A9vAOLP2Tv{A9vA L`Eli Lilly    FTr{A9vAv L`12.485.000  wT,{A9vA L` TT{A9vAwLP TT|+{A9vAOLP3Tx]+{A9vAL\Pfizer   F4Tr+{A9vAv L`12.180.000  w4T,+{A9vA L` TT+{A9vAwLP TT|1_{A9vAOBLP4Tp1u_{A9vABLXAmgen $ FhT1r_{A9vAvB L`10.150.000  whT,1_{A9vAB L` TT1_{A9vAwBLP TT|e{A9vAOvLP5Te{A9vAvLhSanofi-aventis  FTer{A9vAv L`7.159.000  T,e{A9vAv Ld TTe{A9vAvLP TT|{A9vAOLP6T{A9vALlGlaxoSmithKline! $  FTr{A9vA L`6.990.000  T,{A9vA Ld TT{A9vALP TT|{A9vAOLP7T|{A9vAL\Bayer AG !FTr{A9vA L`6.322.430  T,{A9vA Ld TT{A9vALP TT|/{A9vAOLP8T&/{A9vALpBarr Laboratories   F8Tr/{A9vA L`6.290.000  8T,/{A9vA Ld TT/{A9vALP TT|5c{A9vAOFLP9T5c{A9vAF LdRoche Group !FlT5rc{A9vAF L`5.772.772  lT,5c{A9vAF Ld TT5c{A9vAFLP TXqi{A9vADzLP10Ti{A9vAz LdNovartis AG  !FTir{A9vAz L`5.314.420  T,i{A9vAz Ld TTi{A9vAzLP TXq{A9vADLP11T{A9vA L`Merck KGaA# !FTr{A9vA L`4.640.000  T,{A9vA Ld TT{A9vALP TXq{A9vADLP12TP{A9vALtAbbott Laboratories   FTr{A9vA L`4.640.000  T,{A9vA Ld TT{A9vALP TXq3{A9vADLP13T3{A9vA LdAstraZeneca   F<Tr3{A9vA L`4.340.000  <T,3{A9vA Ld TT3{A9vALP TXq9g{A9vADJLP14T9fg{A9vAJLtBristol-Myers Squibb   #  FpT9rg{A9vAJ L`3.545.520  pT,9g{A9vAJ Ld TT9g{A9vAJLP TXqm{A9vAD~LP15Tlm]{A9vA~LXWyeth* FTmr{A9vA~ L`3.302.568  T,m{A9vA~ Ld TTm{A9vA~LP TXq{A9vADLP16T{A9vA LdMedicines Co#   FTr{A9vA L`3.240.000  T,{A9vA Ld TT{A9vALP TXq{A9vADLP17TlO{A9vALXTeva  F Tr{A9vA L`2.210.000   T,{A9vA Ld TT{A9vALP TXq 7{A9vADLP18T %7{A9vALlSchering-Plough    F@T r7{A9vA L`2.160.000  @T, 7{A9vA Ld TT 7{A9vALP TXq=k{A9vADNLP19T=k{A9vAN L`Cephalon   FtT=rk{A9vAN L`1.946.008  tT,=k{A9vAN Ld TT=k{A9vANLP % " !%   ]  TXqq{A9vADLP20Tq{A9vA"LGeneric Pharmaceutical Association!  $    FTqr{A9vA L`1.940.244  T,q{A9vA Ld TTq{A9vALP % " !%   aRp MS Sans Serif0?v x:vfvxz0& &ښ0(&vP(0P(&vN0P(&v(ǭtj0\ 5s Serifߦ0  &" !!(&v'&dv% % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % " !%   \i% % % % % %   TxrS${A9vAE2LTOP 20 CLIENTES FARMACUTICOS PARA LOS "LOBISTAS" !    # !  ! !  T*W{A9vA;LtPROFESIONALES (2008)! ! % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % % " !%   \% %   T {A9vADLFuente: The Center for Responsive Politics y elaboracin de ctsbrief                  % % % " !%   a% " !%   ^'%   &% 6% Ld3!??% 6% Ld1!??%  6 % Ld3 !??%  6 % Ld 1!??% >6>% Ld3-0>!??% >6>% Ld-0>1!??% r6r% Ld3adr!??% r6r% Ldadr1!??% 6% Ld3!??% 6% Ld1!??% 6% Ld3!??% 6% Ld1!??% 6% Ld3!??% 6% Ld1!??% B6B% Ld314B!??% B6B% Ld14B1!??% v6v% Ld3ehv!??% v6v% Ldehv1!??% 6% Ld3!??% 6% Ld1!??% 6% Ld3!??% 6% Ld1!??% 6% Ld3!??% 6% Ld1!??% F6F% Ld358F!??% F6F% Ld58F1!??% z6z% Ld3ilz!??% z6z% Ldilz1!??% 6% Ld3!??% 6% Ld1!??% 6% Ld3!??% 6% Ld1!??% 6% Ld3!??% 6% Ld1!??% J6J% Ld39<J!??% J6J% Ld9<J1!??% ~6~% Ld3mp~!??% ~6~% Ldmp~1!??Ld-X2iR!??Ld`qJ!??Ld`qJ!??Ld`XqJ!??Ld3X_iZ!??Ld3Z!??% 6X% Ldk!??%  6X % Ld k!??% >6X>% Ld-0>k!??% r6Xr% Ldadrk!??% 6X% Ldk!??% 6X% Ldk!??% 6X% Ldk!??% B6XB% Ld14Bk!??% v6Xv% Ldehvk!??% 6X% Ldk!??% 6X% Ldk!??% 6X% Ldk!??% F6XF% Ld58Fk!??% z6Xz% Ldilzk!??% 6X% Ldk!??% 6X% Ldk!??% 6X% Ldk!??% J6XJ% Ld9<Jk!??% ~6X~% Ldmp~k!??Ld3Z!??% ( % " !%   a% ( ( ( " FGDIC" ( " % ( ( " FdXEMF+,@$?W?TaKDbC*@$??@ FGDICF4(EMF+*@$??!b Ld--^)??" FEMF+@